353 results about "Resistant bacteria" patented technology

The invention discloses a full D-type antibacterial peptide with high enzymolysis stability and broad-spectrum antibacterial activity and application thereof. The antibacterial peptide is obtained by sequentially and repeatedly arranging D-type tryptophan, D-type arginine and D-type lysine for four times and carrying out C-terminal amidation; the amino acid sequence of the gene is (D-Trp)-(D-Arg)-(D-Lys)-(D-Trp)-(D-Arg)-(D-Lys)-(D-Trp)-(D-Arg)-(D-Lys)-(D-Trp)-(D-Arg)-(D-Lys)-(D-Trp)-(D-Arg)-(D-Lys)-NH2, and is marked as DWRK-12. The antibacterial peptide shows broad-spectrum antibacterial activity and excellent stability, can effectively resist clinically separated multidrug resistant strains, and keeps high cell selectivity at the same time. Due to the characteristics, the antibacterial peptide has important application value in the aspect of developing novel antibacterial drugs, especially in the field of treatment of infection of multiple drug-resistant bacteria.

The invention relates to a preparation method and application of a carbon dot-based nano enzyme. The preparation method of the carbon dot-based nano-enzyme comprises the following steps: taking sucralose and B vitamins as raw materials, and preparing the carbon dot-based nano-enzyme through a one-pot hydrothermal method. The preparation method of the carbon dot-based nano-enzyme provided by the invention is simpler in catalytic condition and higher in safety. The carbon dot-based nano-enzyme prepared by the invention has the advantages of high oxidase-like activity, low drug resistance, high biocompatibility and the like, can inhibit multi-drug-resistant bacteria, and can be applied to the aspects of aquatic product preservation and the like.

The invention discloses a spatio-temporal trajectory fusion-based closed-loop monitoring method and system for drug-resistant bacteria in a hospital. The method comprises the following steps: collecting and processing strain drug sensitive test results and patient clinical index data in a hospital information system, and screening out key features through an improved genetic algorithm; wherein the clinical index data of the patient comprises original spatio-temporal trajectory data and nursing operation records; analyzing spatio-temporal trajectory data of the patient according to the key features, combining with drug sensitivity spectrum consistency, and constructing a propagation network model by using a graph convolutional network to identify infection source nodes and corresponding topological influence; and generating an early warning signal based on the topological influence of the infection source node, and continuously optimizing prevention and control measures by dynamically adjusting model parameters and a real-time feedback mechanism. By implementing the method provided by the invention, accurate analysis and real-time prevention and control of a drug-resistant bacterium transmission link can be realized.

The invention relates to the technical field of Escherichia coli drug resistance analysis, in particular to an Escherichia coli antibiotic drug resistance detection method based on SERS and machine learning. The invention provides an Escherichia coli antibiotic resistance detection method based on SERS (Surface Enhanced Raman Scattering) and machine learning so as to overcome the defect that high-precision and rapid diagnosis cannot be realized in the prior art. The invention aims to realize rapid and high-precision identification of drug-resistant bacteria through a machine learning algorithm by utilizing a core-shell nanostructure SERS substrate of silver-coated gold nanoparticles and combining SERS spectrum differences of drug-resistant escherichia coli with different phenotypes. Through the method, the detection time can be remarkably shortened, the detection precision can be improved, an accurate drug treatment scheme is provided for clinic, and the method has a wide application prospect.

The invention discloses a bacillus strain H7 and an application thereof. The invention provides bacillus velezensis H7 or a progeny of the bacillus velezensis H7, and the preservation number of the bacillus velezensis H7 in the China Center for Type Culture Collection (CCTCC) is CCTCC NO: M 2025630. The bacillus velezensis H7 disclosed by the invention has a very good antibacterial effect on various common clinical pathogenic bacteria (including klebsiella pneumoniae, escherichia coli, candida albicans, enterobacter cloacae complex, acinetobacter baumannii and the like), and particularly shows a very high inhibition rate on some drug-resistant clinical pathogenic bacteria; therefore, the compound has important application value in development of drug and non-drug antibacterial products (such as medical antibacterial materials and the like), a new choice can be provided for drug and non-drug prevention and control of clinical pathogenic bacterium infection, and particularly, the compound has a supplementary effect in the aspects of reducing drug-resistant bacterium propagation risk and reducing drug dependence.

The invention belongs to the technical field of antibacterial peptides, and particularly relates to an LL-37 derived antibacterial peptide and application thereof. According to the invention, 17-29aa of the LL-37 antibacterial peptide is used as a core fragment and is connected with an amino acid sequence shown as SEQ ID NO: 1 or SEQ ID NO: 2 through an amido bond, the antibacterial activity of the obtained antibacterial peptide is obviously higher than that of the LL-37 antibacterial peptide, and the antibacterial peptide shows an obvious bactericidal effect on clinical drug-resistant bacteria such as acinetobacter baumannii, pseudomonas aeruginosa, escherichia coli, staphylococcus aureus, klebsiella pneumoniae and the like; meanwhile, the cytotoxicity and hemolytic activity are weak, drug resistance is not prone to being generated, bacteria can be rapidly killed in vivo through multiple mechanisms, no obvious cytotoxicity exists, the bacterium load in tissue is remarkably reduced, and the lifetime of a bacterium-infected mouse is prolonged.

The invention discloses an application of NSC348884 in preparation of an antibacterial drug, the bacteria of the NSC348884 are gram-negative bacteria or drug-resistant gram-negative bacteria, and the gram-negative bacteria are acinetobacter baumannii, escherichia coli, pseudomonas aeruginosa or klebsiella pneumoniae; based on an antibacterial drug high-throughput screening technology, it is found from 1280 small molecule compounds that the benzimidazole compound NSC348884 has direct bacteriostasis and sterilization effects on gram-negative bacteria and drug-resistant gram-negative bacteria, and no drug resistance is generated after the benzimidazole compound NSC348884 is continuously applied for 14 days. Further research shows that NSC348884 can interfere with lipid synthesis of gram-negative bacterium cell membranes, inhibit formation of biological membranes and induce lipid metabolism disorder, so that bacteriostatic and bactericidal effects are achieved. In addition, the NSC348884 can also enhance the sensitivity of the drug-resistant bacteria to the imipenem and the polymyxin B.

The invention discloses application of a method for enhancing the treatment effect of salmonella bacteriophage, and relates to the technical field of microorganisms. According to the method, bacteriophage is added into salmonella for in-vitro culture, after continuous subculture, the salmonella is dropwise added to an SS plate containing the bacteriophage, and resistant bacteria of the bacteriophage are screened. The split bacteriophage is screened aiming at the resistant bacteria of the bacteriophage, and the split bacteriophage and the initial bacteriophage form a bacteriophage cocktail formula, so that the salmonellosis can be well prevented and treated, and the generation of the resistant bacteria is delayed. The method has the beneficial effects that compared with the existing method for screening the bacteriophage-resistant bacteria through a double-layer plate method, the method is more convenient, the operation is simple, and the screening efficiency of the bacteriophage-resistant bacteria is greatly improved. The bacteriophage cocktail contains the bacteriophage for cracking the resistant bacteria, so that the treatment effect of the bacteriophage is improved, and the practical application scene is quite high.

The invention discloses bioactive gel for accelerating wound healing. The gel is prepared from the following raw materials in percentage by weight: 0.8%-1% of bomer 980, 5%-5.5% of glycerol, 15%-20% of white vaseline, 51.7%-55% of phosphate buffer, 1.8%-2% of nano royal jelly acid, 2%-3% of recombinant III type human collagen, 0.4%-0.5% of sodium hyaluronate, 1%-3% of sodium alginate, 20%-25% of polyethylene glycol-400, 1.5%-3% of dopamine-methacrylamide copolymer, 0.5%-0.8% of nano silver and 0.3%-0.5% of phenoxyethanol. The nano royal jelly acid and the nano silver have a synergistic antibacterial effect, so that the inhibition effect on drug-resistant bacteria such as MRSA and pseudomonas aeruginosa is remarkably improved, and meanwhile, the wound epithelization can be accelerated and scar formation can be reduced through the dual effects of the recombinant III type collagen and the acetylated sodium hyaluronate. The defects that a traditional dressing is narrow in antibacterial spectrum, single in repairing effect, poor in environmental adaptability and the like are overcome, and the dressing is particularly suitable for complicated wounds such as diabetic foot ulcer and second-degree burn.

The invention relates to the field of drug-resistant bacterium infection, and discloses a g-C3N4 / Bi2Se3 nano heterojunction and a preparation method thereof.The preparation method comprises the steps that firstly, melamine powder is heated and calcined at the constant temperature, after a tubular furnace is naturally cooled, spark plasma sintering is conducted, nitrogen vacancies are introduced at the same time, and a blocky high-defect g-C3N4 material is obtained; grinding into powder, adding deionized water for ultrasonic treatment to obtain a first suspension, performing centrifugal treatment, freeze-drying the supernatant, and adding into an ethylene glycol solvent to obtain a second suspension; eG, polyvinylpyrrolidone, Bi (NO3) 3.5 H2O and Na2SeO3 are mixed and stirred, and the second turbid liquid is added; the preparation method comprises the following steps: adding Bi2Se3 into a reaction kettle, heating while stirring, adding a hydroxylamine EG solution, cooling to room temperature after reaction, centrifuging, washing, and carrying out vacuum drying on a precipitate to obtain a g-C3N4 / Bi2Se3 nano heterojunction; the problems that in the prior art, the catalytic efficiency is low, a collaborative mechanism does not achieve structure-function integrated design, the performance of a key functional material is limited, and the structural stability and biological suitability of the material are insufficient are solved.

The invention discloses an early warning method and system for outbreak of drug-resistant bacteria in a hospital based on dynamic aggregation degree evaluation. The method comprises the following steps: acquiring hospitalization information of a patient, microbiological inspection data and spatial layout information of an inpatient area to obtain initial data; judging whether a new case of drug-resistant bacteria is detected on the current day; if not, gradually reducing the historical aggregation degree by using an exponential decay formula until the historical aggregation degree returns to zero; if yes, calculating a newly added detection rate, a space aggregation degree and a time aggregation degree, and calculating a total aggregation degree of the day; dividing an inpatient area; dynamically generating a threshold value for the high-frequency inpatient area by adopting a quartile method to carry out abnormal value judgment, and identifying an abnormal aggregation degree for the low-frequency inpatient area by using a fixed absolute value threshold mechanism to obtain an early warning level; and early warning information of different levels is pushed according to the early warning level, and a prevention and control suggestion plan is attached. By implementing the method provided by the invention, the accuracy and efficiency of early warning can be remarkably improved, so that patients and medical personnel are better protected from the threat of drug-resistant bacterium infection.

The invention relates to an antibacterial peptide and application thereof. The amino acid sequence of the antibacterial peptide is as shown in SEQ ID No. 1. The antibacterial peptide has excellent broad-spectrum antibacterial activity, for example, the antibacterial peptide has antibacterial activity on bacteria of the genus Staphylococcus (Staphylococcus), the genus Acinetobacter (Acinetobacter) and the genus Bacillus (Bacillus). Under the background that the global bacterial drug resistance problem is increasingly severe and traditional antibiotics gradually lose efficacy on multi-drug-resistant bacteria, a new treatment means is provided for treating bacteria such as methicillin-resistant staphylococcus aureus, carbapenem-resistant acinetobacter baumannii and bacillus subtilis which bring huge threats to public health. And a new possibility is provided for solving the problem that no medicine can be used clinically.

The present invention relates to the pharmaceutical field, and provides a boric acid β-lactamase inhibitor or a use thereof. The boric acid β-lactamase inhibitor is a compound shown in formula (I), or an optical isomer or a pharmaceutically acceptable salt thereof: formula (I). The ultra-broad-spectrum boric acid β-lactamase inhibitor of the present invention has an inhibition effect on A, B, C, and D enzymes, and carbapenem drug-resistant bacteria such as Klebsiella pneumoniae, Escherichia coli, Enterobacter cloacae, Acinetobacter baumannii, and Pseudomonas aeruginosa.

The invention discloses a polyketone compound derived from actinomycetes as well as a preparation method and application thereof, and relates to the technical field of microbial natural product mining and biological medicine, and the key point of the technical scheme is that the invention discloses a novel polyketone compound Strepactone derived from actinomycetes Streptomyces sp. DP0001, and the molecular formula of the novel polyketone compound Strepactone is C25H38O5. The compound is obtained through strain fermentation, ethyl acetate extraction and multi-step chromatographic purification, and the structure is identified through ESI-MS, 1H NMR and 13C NMR. Experiments show that Strepactone has an inhibition effect on staphylococcus aureus and methicillin-resistant staphylococcus aureus and has remarkable inhibition activity on human non-small cell lung cancer A549 cells, the half inhibitory concentration IC50 of the Strepactone is 5.36 mu M, and the Strepactone has no obvious cytotoxic activity on human embryo kidney cells 293T cells at the concentration of 30 mu M. The compound provided by the invention can be used for preparing anti-drug-resistant bacteria drugs and anti-human non-small cell lung cancer drugs, and also provides a structural basis for the development of novel antibacterial and anti-tumor leading drugs.

The application relates to the technical field of wastewater treatment, and particularly discloses a degradation method and application of microplastics in aquaculture wastewater. The degradation method comprises the steps of preparation of a mesoporous structure magnetic immobilized material, pretreatment, adsorption-enzymolysis, microbial degradation, magnetic separation, precipitation and the like. The shell layer and the mesoporous structure of the mesoporous material are used to efficiently immobilize composite enzymes, so that enzyme loss is avoided, and the composite enzymes are used for targeted degradation of PET, PE and PP, and the total microplastic removal rate is more than 94.5%. The composite heat-resistant bacteria relay enzymolysis product is deepened and mineralized, and a phased treatment agent is matched to enhance mass transfer, so that the microbial activity is increased by 3 times. The mesoporous material is protected by the shell layer, the enzyme activity retention rate is more than 85%, the effluent COD is less than or equal to 50 mg / L, meets the discharge requirements, is suitable for microplastic pollution treatment in multiple scenes, and has the advantages of high efficiency, economy and environmental friendliness.

The invention provides a method for synchronously and rapidly detecting Escherichia coli and multiple drug-resistant genes thereof, which comprises the following steps: culturing a sample at night to obtain a bacterial solution to be detected, adding a buffer solution and a metal bath, centrifuging, taking a supernatant, detecting by micro-fluidic, optimizing the extraction process of nucleic acid in the sample, designing an optimal RPA primer probe group, and detecting the multiple drug-resistant genes of the Escherichia coli. A reasonable RPA coupled microfluidic detection system is established, synchronous and rapid detection of the escherichia coli uidA and I-type integrase gene intI1 thereof and drug-resistant genes sul1 and aadA5 is realized, the specificity is high, the sensitivity is high, the reaction time is short, the operation is convenient, and a method support is provided for monitoring and prevention and control of food-borne drug-resistant bacteria.

This invention relates to a 1,3,4-thiadiazole peptide deformylase inhibitor and its preparation and application. The structural formula is shown in formula (1): wherein, R 1 It is n-butyl or cyclopentylmethyl; R 2 The compounds are hydrogen-containing, straight-chain alkanes, cyclic alkanes, aromatic rings, substituted biphenyls, or heterocyclic rings. The 1,3,4-thiadiazole peptide deformylase inhibitors provided by this invention can effectively inhibit bacterial protein synthesis, thereby achieving sterilization. These compounds exhibit excellent inhibitory activity against Gram-positive drug-resistant bacteria, especially the clinically challenging methicillin-resistant Staphylococcus aureus (MRSA). In particular, some preferred compounds show inhibitory activity 4-8 times that of the control standards vancomycin and linezolid. The 1,3,4-thiadiazole peptide deformylase inhibitors provided by this invention also exhibit inhibitory activity against Gram-negative drug-resistant bacteria, especially against drug-resistant Acinetobacter baumannii, known as "superbugs," with an inhibitory activity reaching 0.5 μg / mL, far superior to vancomycin and linezolid.

To provide a detection method capable of rapidly detecting drug-resistant bacteria, bacteria of the genus Staphylococcus, and bacteria of the genus Pseudomonas; a method for providing an index for selecting an antimicrobial agent for bacteria; and a primer set usable in these methods.SOLUTION: The detection method for drug-resistant bacteria, bacteria of the genus Staphylococcus, and bacteria of the genus Pseudomonas according to the present disclosure comprises a step of performing nucleic acid amplification of target genes (1) to (3) and (4) below for a target sample, and detecting drug-resistant bacteria, bacteria of the genus Staphylococcus, and bacteria of the genus Pseudomonas in the sample: (1) the mecA gene; (2) the spa gene of Staphylococcus aureus; (3) the tuf gene and / or the rpoB gene of bacteria of the genus Staphylococcus; and (4) the 16S rRNA gene of bacteria of the genus Pseudomonas.SELECTED DRAWING: Figure 1

The application provides a preparation method of a high-efficiency piezoelectric coating on a titanium implant surface. The preparation method of the application uses a hydrothermal treatment and an in-situ piezoelectric deposition technology to in-situ synthesize a nano strontium titanate-noble metal piezoelectric coating on the titanium implant surface. The coating can generate a piezoelectric potential and active oxygen through ultrasonic driving to degrade extracellular polymers and kill bacteria. In addition, the piezoelectric coating can also promote the osteogenic differentiation of bone marrow mesenchymal stem cells under piezoelectric stimulation, and finally realize the effects of bioactivity, long-acting drug-resistant bacteria and high-efficiency bone integration in the body. The application can provide a new surface treatment technology and research idea for controlling the drug-resistant bacteria infection on the implant surface, help to break through the limitations of the existing theory and technology in removing bacterial infection on the titanium implant surface, and provide beneficial guidance for the control of bacterial biofilm on other parts and the prevention and treatment of related infectious diseases.

This invention belongs to the field of resource utilization technology, specifically relating to a low-temperature composting self-heating start-up compound microbial agent, its preparation method, and its application. The low-temperature composting self-heating start-up compound microbial agent is composed of *Broodia buddingis* (…). Aureobasidium sp.X4-8) and Bacillus licheniformis ( Bacillus licheniformis The compound microbial agent (H-29) was prepared by combining two bacterial groups. The two bacterial groups exhibited dominance and functional complementarity at different temperature stages. When added at -30℃, the psychrophilic fungi initially "ignited" the heat, and as the compost temperature exceeded 40℃, the heat-resistant bacteria rapidly took over and released lignin peroxidase and manganese peroxidase, achieving continuous regulation of the composting system from initial heating and high-temperature maintenance to deep decomposition under low-temperature conditions. Aerobic composting of agricultural waste using the compound microbial agent resulted in a seed germination index (GI) ≥ 70% for the decomposed product, with all indicators meeting the NY / T 525-2021 standard.

The application discloses antibacterial carbon dots and a low-temperature and normal-pressure preparation method and application thereof. The method is characterized in that ascorbic acid and cetylpyridinium chloride are used as raw materials, and the antibacterial carbon dots are synthesized through a low-temperature and normal-pressure method. The preparation method has the advantages of simple process, low reaction temperature, short reaction time, no need for any functional modification and low cost. The prepared carbon dots have good water solubility and excellent antibacterial activity. In particular, the carbon dots exhibit significant antibacterial activity on drug-resistant bacteria, can inactivate the drug-resistant bacteria through multiple ways such as destroying cell membranes, inducing active oxygen and reducing the surface charge of bacteria, and have a good application prospect in antibacterial aspects.

The application discloses a psoralen derivative or a pharmaceutical salt thereof, and a structure general formula of the psoralen derivative is shown in the following formula: The psoralen derivative is obtained by optimizing the structure of psoralen, and the antibacterial activity test is carried out on common gram-positive bacteria such as drug-resistant staphylococcus aureus and gram-negative bacteria such as escherichia coli and klebsiella pneumoniae, and it is found that the compound or the pharmaceutical salt thereof has excellent anti-drug-resistant bacteria, anti-inflammatory and anti-tumor activities, and has good development value in preparation of anti-infection treatment drugs, anti-inflammatory drugs and anti-tumor drugs.

The invention relates to a bimetallic alloy nano-enzyme for treating multi-drug-resistant bacterial infection as well as a preparation method and application thereof, and belongs to the field of biomedical nano-materials. The problems that in the prior art, the catalytic activity of metal and metal-based nano enzyme is limited, the bactericidal effect is poor due to poor targeting performance, the bactericidal effect in vivo (especially deep drug-resistant bacteria) is poor, and biocompatibility is poor are solved. The invention relates to a bimetallic alloy nano-enzyme for treating multidrug-resistant bacterial infection, which is mainly composed of two metal elements of Pt and Ru, and the atomic ratio of Pt / Ru is 90 / 10-70 / 30. The bimetallic alloy nano-enzyme disclosed by the invention has efficient biological catalytic activity, has a very good treatment effect on deep drug-resistant bacterial infection under ultrasonic activation, shows remarkable antibacterial, anti-biofilm and anti-inflammatory multiple effects, and is good in biocompatibility.

The present application belongs to the technical field of biomedical materials, and particularly relates to a composite extracellular trap antibacterial dressing and a preparation method thereof. The composite extracellular trap antibacterial dressing comprises a hydrogel and an extracellular trap loaded in the hydrogel. The antibacterial dressing can actively capture and efficiently kill bacteria including drug-resistant bacteria, is a novel dressing biological sterilization mechanism, has good biocompatibility, and can accelerate wound healing.

The invention discloses application of lactobacillus plantarum LP-Y01 and a fungicide thereof in preparation of a medicine for preventing and / or treating carbapenem-resistant drug-resistant bacterium infection. The invention verifies that the lactobacillus plantarum can generate a direct inhibition effect on carbapenem-resistant klebsiella pneumonia in vitro and has certain effective activity on colonization of the carbapenem-resistant klebsiella pneumonia in vivo through flora regulation and control. Probiotic pretreatment shows remarkable clinical potential by regulating and controlling a flora structure, provides a precise strategy for prevention and control of drug-resistant bacteria, and has a relatively good application prospect.

The invention relates to the technical field of biological medicine, in particular to application of flufenamic acid in preparation of a polymyxin E antibacterial synergist. The invention discloses an application of flufenamic acid in preparation of a polymyxin E antibacterial synergist, the flufenamic acid has no obvious antibacterial effect on salmonella when being independently used, but the flufenamic acid and polymyxin E can enhance the antibacterial activity of the polymyxin E on the salmonella and reduce the use dosage of the polymyxin E when being jointly used in and out of an animal body, so that the antibacterial effect of the polymyxin E on the salmonella can be enhanced. The antibacterial activity of the polymyxin E on salmonella is enhanced, and the drug resistance of the polymyxin E is inhibited. Flurfenamic acid is approved to be used for other purposes as FDA, and when the flurfenamic acid is combined with polymyxin E, the flurfenamic acid has the characteristic of high safety, and meanwhile, the generation of the drug resistance of the polymyxin E drugs can be effectively avoided. The invention provides a basis for mining a new antibacterial prevention and control strategy for the polymyxin E drug-resistant bacteria.

This invention relates to a method for preparing medical nanozymes, the medical nanozymes themselves, their applications, and pharmaceuticals, belonging to the field of biomedicine. It addresses at least one of the following problems in existing technologies for treating deep tissue infections caused by drug-resistant bacteria: poor antibacterial and anti-biofilm effects, insufficient deep tissue penetration, lack of inflammation regulation and tissue repair functions, biosafety risks, and high material preparation costs. The preparation method includes: mixing rhodium trichloride, urea, and polyvinylpyrrolidone to obtain a mixture; subjecting the mixture to staged pyrolysis under inert gas protection to obtain a nitrogen-doped carbon-supported single-atom rhodium catalyst; and modifying the nitrogen-doped carbon-supported single-atom rhodium catalyst with polyethylene glycol. The medical nanozymes prepared by this invention achieve excellent antibacterial and anti-biofilm effects both in vivo and in vitro, can regulate the inflammatory microenvironment, promote tissue repair, exhibit good biocompatibility, and have strong tissue penetration ability.

The invention belongs to the technical field of natural antibacterial drugs, and discloses application of cyclovirobuxine D and pharmaceutically acceptable salts thereof in preparation of antibacterial drugs. The invention discloses the effect of cyclovirobuxine D in preparation of antibacterial drugs, and tests prove that cyclovirobuxine D has remarkable antibacterial activity in inhibition of gram-positive bacteria such as staphylococcus aureus, gram-negative bacteria such as escherichia coli and super drug-resistant bacteria such as MRSA (Methicillin Resistant Staphylococcus Aureus).